Did you know that osteoarthritis (OA) most frequently occurs after the age of 40 years? The prevalence of this degenerative joint disease rises sharply with age. Consequently, many individuals experience joint pain and swelling due to OA, prompting them to seek effective solutions.
Although the medical field has not yet discovered a cure for osteoarthritis (OA), many companies have developed innovative treatments for temporary symptomatic relief. Notably, Anika Therapeutics introduced Monovisc knee injections to alleviate the symptoms of knee OA. This treatment aims to enhance individuals’ quality of life by offering long-lasting relief.
This article will dive into the Monovisc injection manufacturer, Anika Therapeutics, its history, mission, and contributions to orthobiologics and commitment to quality, innovation, and patient safety.
Key Takeaways
- This joint preservation company pursued creating and delivering advancements for orthopedics, including addressing osteoarthritis (OA) and its symptoms.
- Anika Therapeutics has continued to advance in joint preservation solutions, earning CE marks and US FDA approvals, highlighting its products’ safety and efficacy.
- Anika Therapeutics pioneered viscosupplementation injectables, such as Orthovisc, Cingal, and Monovisc knee injections, each with different formulations.
- Monovisc knee injection offers a convenient single-injection therapy to treat knee osteoarthritis (OA) symptoms such as pain, swelling, and limited mobility.
- By seeking the approval of these agencies, Anika Therapeutics prioritizes patient safety while adhering to the stringent global regulatory requirements for its products.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. If you’re looking to buy Monovisc, our dedicated sales agents can give you proper guidance. We offer a worry-free experience in searching for the best and most popular products on the market. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Introduction to Anika Therapeutics
Anika Therapeutics has been in the medical field for decades and continuously delivers early-intervention orthopedic products. They have helped many individuals restore active living around the globe.
This joint preservation company pursued creating and delivering advancements for orthopedics, including addressing osteoarthritis (OA) and its symptoms. Anika offers minimally invasive solutions in early intervention orthopedic care. These categories include the following:
- Arthrosurface Joint Solutions
- Sports Medicine
- Regenerative Solutions
- OA Pain Management
- Non-Orthopedic Solutions
These products help manage pain and symptoms and delay the need for invasive or surgical procedures. Backed by its mission of developing meaningful advancements, Anika Therapeutics’ vision is to be the global leader in joint preservation solutions that restore individuals’ active, daily lives.
History of Anika Therapeutics
Since its incorporation in 1992, Anika Therapeutics has emerged as a market leader in joint preservation. When it started, Anika focused on manufacturing and supplying Johnson & Johnson’s hyaluronic acid-based ophthalmic products.
After manufacturing, supplying, and distributing, Anika launched its first hyaluronic acid-based viscosupplement in 1996 — Orthovisc. This received CE mark approval and reached internationally for treating osteoarthritis (OA) pain. In 2001, Arthrosurface was established and incorporated, while Orthovisc obtained US Food and Drug Administration approval in 2004.
Four years later, the single-injection therapy Monovisc received the CE mark approval in Europe. In 2014, this viscosupplement earned the US FDA approval and was launched as the first non-animal-sourced HA for knee OA. Before this approval, Anika Therapeutics earned approval for other products and acquired technologies.
Cingal’s HA-based viscosupplement with steroid combination and Orthovisc-T was launched in 2016. In 2020, Anika acquired Arthrosurface and Parcus Medical, a provider of joint preservation solutions and a sports medicine company, respectively.
Anika Therapeutics has continued to advance in joint preservation solutions, earning CE marks and US FDA approvals, highlighting its products’ safety and efficacy.
Anika Therapeutics’ Contributions to Orthobiologics
This company has significantly advanced orthobiologics through innovative research and development. Anika’s R&D focuses on orthopedic care, including regenerative solutions and hyaluronic acid-based products. These minimally invasive treatments for osteoarthritis pain management and regenerative solutions include:
- Orthovisc
- Monovisc
- Cingal
- Tactoset
- Hyalofast
Notably, Anika Therapeutics pioneered viscosupplementation injectables, such as Orthovisc, Cingal, and Monovisc knee injections, each with different formulations. They effectively developed Orthovisc’s multi-injection therapy, Cingal’s combination treatment, and Monovisc’s single-injection cycle.
Monovisc Knee Injection
Monovisc knee injection offers a convenient single-injection therapy to treat knee osteoarthritis (OA) symptoms such as pain, swelling, and limited mobility. This viscosupplement contains ultra-pure, non-animal-sourced, and partially crosslinked hyaluronan.
When comparing Monovisc vs Orthovisc, it’s worth noting that a single-injection therapy appeals more to medical professionals and patients. Monovisc’s FDA approval also urges individuals to select this treatment for its proven efficacy and safety. Moreover, it can deliver various benefits, such as:
- Long-lasting Treatment Outcomes
- Improved Joint Mobility and Function
- Reduced Joint Pain and Inflammation
- Quick Procedure and Downtime
- Minimized Potential Risks
- Enhanced Quality of Life
The biocompatibility and resorbability of Monovisc also highlight its safe and efficient process in treating OA symptoms among patients. However, medical professionals must administer this product to maximize its benefits and patient safety.
Commitment to Quality and Patient Safety
Anika Therapeutics is committed to maintaining the highest quality standards in all business aspects, from product development to customer service. They showcase this dedication through continuous research and development and earning approvals from CE and FDA.
By seeking the approval of these agencies, Anika Therapeutics prioritizes patient safety while adhering to the stringent global regulatory requirements for its products. The company ensures that Monovisc knee injections and other products comply with the regulations and high-quality standards set by the FDA and CE.
Conclusion
Monovisc’s manufacturer, Anika Therapeutics, has established itself as a pioneer in developing innovative orthopedic care solutions, particularly in osteoarthritis management. Through its commitment to quality, patient safety, and ongoing research and development, Anika Therapeutics has introduced products like Monovisc knee injections, offering long-lasting relief and improved quality of life for individuals suffering from knee osteoarthritis.
The company’s extensive history, focus on orthobiologics and dedication to advancing regenerative solutions underscore its leadership and meaningful contributions to the medical community. As Anika Therapeutics continues to push the boundaries of orthopedic care, it reaffirms its vision of becoming the global leader in joint preservation solutions and restoring active lives for individuals worldwide.
FAQs
1. What is Monovisc?
Monovisc is a viscosupplement injection intended to alleviate symptoms of knee osteoarthritis, such as pain, swelling, and limited mobility. It contains ultra-pure, non-animal-sourced, and partially crosslinked hyaluronan.
2. Who is the manufacturer of Monovisc knee injections?
Monovisc knee injections are manufactured by Anika Therapeutics, a company specializing in joint preservation solutions and orthobiologics.
3. What is Anika Therapeutics’ commitment to quality and patient safety?
Anika Therapeutics is committed to maintaining the highest quality and patient safety standards in developing and manufacturing its orthopedic care products, including Monovisc knee injections.
References
- GBD 2021 Osteoarthritis Collaborators (2023). Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. Rheumatology, 5(9), e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7
- History – Anika Therapeutics. (n.d.). Anika.com. Retrieved August 9, 2024, from https://anika.com/about-anika/history/
